About This Program
This program aims to develop anti-Galectin-9 therapeutic monoclonal antibody for immuno-oncology.
Galectin-9 (Gal-9) is a major inhibitor of the immune system and exerts its immunosuppressive effects in many cells of the immune system. Recent studies have shown that abnormal expression of Gal-9 is associated with certain primary cancers. Abnormal expression of Gal-9 is involved in the regulation of cell adhesion and aggregation. Once produced by cancer cells and other cells of the microenvironment, Gal-9 is released into the circulation and exert its systemic effect on the immune system. Its inhibition can have multiple anti-tumor effects.
Galectin-9
Galectin-9 (Gal-9) is a member of the β-galactoside-binding galectin family and plays a role in immune response, apoptosis, cell proliferation, and cell death. T cell immunoglobulin (Ig) and mucin domain-containing molecule 3 (Tim-3) are inhibitory receptors expressed on the surface of T cells and are essential for inhibiting T cell responses to tumors. Galectin-9 has been identified as a ligand for Tim-3, and binding of galectin-9 to Tim-3 results in apoptosis of T cells and negative regulation of T cell immunity.
